Abstract
Soft tissue sarcomas are rare tumors. There is a lot of histologic varieties but the natural history and the prognosis are very similar. Surgery remains the first step of the treatment policy. Radiotherapy, given additionally, can prevent local relapse. Till now, chemotherapy was given to patientes with advanced diseases. Except doxorubicine and ifosfamide much drugs act poorly in the solft tissue sarcomas. CYVADIC is the best combination available. One randomized study has established the value of adjuvant chemotherapy in soft tissue sarcomas of the extremities. The real place of chemotherapy, probably will be in the next years, beside surgery and radiotherapy, in a multidisciplinary combined approach.
MeSH terms
-
Alkylating Agents / therapeutic use
-
Antibiotics, Antineoplastic / therapeutic use
-
Antimetabolites, Antineoplastic / therapeutic use
-
Antineoplastic Agents, Phytogenic / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / therapeutic use
-
Cyclophosphamide / administration & dosage
-
Dacarbazine / administration & dosage
-
Doxorubicin / administration & dosage
-
Humans
-
Naphthacenes / therapeutic use
-
Nitrosourea Compounds / therapeutic use
-
Premedication
-
Sarcoma / drug therapy*
-
Sarcoma / pathology
-
Soft Tissue Neoplasms / drug therapy*
-
Soft Tissue Neoplasms / pathology
-
Vincristine / administration & dosage
Substances
-
Alkylating Agents
-
Antibiotics, Antineoplastic
-
Antimetabolites, Antineoplastic
-
Antineoplastic Agents, Phytogenic
-
Naphthacenes
-
Nitrosourea Compounds
-
Vincristine
-
Dacarbazine
-
Doxorubicin
-
Cyclophosphamide
-
Cisplatin